Evidence map›Paper›PMID 27021020›Full record

ArticleMolecular neurobiology2017

RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.

Chunling Jiang, Tao Song, Jingao Li, Fan Ao, Xiaochang Gong, Yicheng Lu, Chenran Zhang, Liangyu Chen, Yunhui Liu, Hua He and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Preclinical Models of Meningioma.Advances in experimental medicine and biology · 2023
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Chunling JiangDepartment of Radiation Oncology, Nanchang University, Nanchang, 330006, China.
Tao SongDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410000, China.
Jingao LiDepartment of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, 330029, China.
Fan AoDepartment of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, 330029, China.
Xiaochang GongDepartment of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, 330029, China.
Yicheng LuDepartment of Neurosurgery, Changzheng Hospital, Second Affiliated Hospital of Military University, No 440 North Chengdu Road, Huangpu District, Shanghai, 200003, China.
Chenran ZhangDepartment of Neurosurgery, Changzheng Hospital, Second Affiliated Hospital of Military University, No 440 North Chengdu Road, Huangpu District, Shanghai, 200003, China.
Liangyu ChenDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.
Yunhui LiuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.
Hua HeDepartment of Neurosurgery, Changzheng Hospital, Second Affiliated Hospital of Military University, No 440 North Chengdu Road, Huangpu District, Shanghai, 200003, China. hh_hehua@sina.com.
Ouping HuangKey Laboratory of Women's Reproductive Health of Jiangxi, Jiangxi Provincial Maternal and Child Health Hospital, No 318 Bayi Avenue, Nanchang, 330006, China. ouping_huang@126.com.
Jiangxi Provincial Cancer Hospital · CNChina Medical University · CNSecond Military Medical University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we investigated the influence of elevated RAS expression on the growth of meningioma in vivo and in vitro. The IOMM-LEE cells, representing a cell line derived from malignant meningioma, were divided into blank control group (cells without any drug treatment), negative control group (cells treated with an equal volume of normal saline to replace drug), and farnesyl thiosalicylic acid (FTS)-treated group (cells treated with FTS). Methyl-thiazole-tetrazolium bromide (MTT) assay and flow cytometer (with cells after FTS (75 μmol/L) treatment for 48 h) were utilized to determine the proliferation and apoptosis, respectively, of IOMM-LEE cells after RAS inhibition. Western blot analysis was used for semi-quantitative analysis of p-ERK and p-AKT levels. Animal model of human meningioma was established with sub-renal capsule transplantation, and mice were divided into two groups: experimental group (50 mg/kg group, 75 mg/kg group, and 100 mg/kg, hypodermic injection with FTS) and control group. Proliferating cell nuclear antigen (PCNA) was detected by immunohistochemistry (IHC). Western blot analysis was used for detecting ERK and AKT signal pathway. The proliferation of IOMM-LEE cells decreased dramatically and apoptosis rate increased significantly in FTS-treated group compared to blank control group and negative control group (all P < 0.05). At FTS concentration of 75 μmol/L, the apoptosis rate of IOMM-LEE cells reduced significantly over time (P < 0.05). Cell cycle analysis showed that IOMM-LEE cells exhibited G1-arrest in the FTS-treated group, compared to no cell-cycle arrest in blank control group and the negative control group (P < 0.05). Further, significantly decreased ERK and AKT phosphorylation levels were detected in IOMM-Lee cells after FTS (75 μmol/L) treatment for 48 h, compared to blank control group and negative control group (P < 0.05). The results in vivo experiments showed that after FTS treatment, tumor volume, PCNA LI, and the levels of p-ERK and p-Akt decreased significantly in 75 mg/kg group and 100 mg/kg group when compared with the control group and 50 mg/kg group (all P < 0.05). Our findings provide strong evidence that RAS protein is highly expressed in meningioma cells, and the RAS activity is inhibited by downregulating ERK and AKT signal pathway, which may further inhibit the growth of meningioma.

Indexed as

AdultAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationDouble-Blind MethodFarnesolFemaleHumansMaleMeningeal NeoplasmsMeningiomaMiceMice, Inbred BALB CMice, NudeAntineoplastic AgentsFarnesolfarnesylthiosalicylic acidras ProteinsSalicylatesAKT proteinERK proteinIOMM-LEEMeningiomaRAS protein

Identifiers

PMID27021020
OpenAlexW2314275406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.